Skip to content

Shutdown will Impact FDA


The looming government shutdown will likely slow the pace of work at the FDA. The federal government will shut down on October 1, 2023 unless a deal is reached. In the event of a shutdown, 19% of FDA employees would be furloughed immediately.

Many FDA activities would continue via user fee funding. These activities relate to regulation of drugs, biosimilars, medical devices, and tobacco products. Additionally, COVID-19 supplemental funding will ensure that certain pandemic response activities would continue. Together, the user fee funding and COVID-19 funding can provide for 64% of the FDA workforce—the exempted staff. It is possible, however, that these sources of funding may run out if the shutdown is extended.

The FDA also has excepted staff, totaling 17% of the FDA’s workforce, who can continue their activities even without appropriations. This ensures that all “vital” activities can also continue in the event of a shutdown. These activities relate to detection and response to health emergencies, addressing existing critical health challenges, managing recalls, drug shortages, and outbreaks relating to foodborne illness and infectious disease. Other vital activities include pursuing criminal enforcement work and civil investigations, reviewing import entries, conducting inspections of regulated facilities, and surveilling for adverse events reports.

Medical product activities are supported by a mix of user fees and appropriations. It seems reasonable to expect some of the FDA’s employees working in this area would be furloughed. Additionally, new applications for devices covered by the agency’s 510(k) and Premarket Approval (PMA) will not be accepted during the shutdown, similarly to the previous shutdown.

Notably, the percentage of the FDA employees to be immediately furloughed upon commencement of the shutdown is lower than it was during the 2018-2019 shutdown, when 41% of the workforce was furloughed. Based on the 2018-2019 shutdown, some commenters have speculated that FDA personnel may be less responsive to electronic communications should the shutdown occur.

Likely Order of Events as the Shutdown Persists:

  • October 1, 2023 — 19% of FDA employees are immediately furloughed; new device applications not accepted.
  • Months later — Some of the exempted employees (64% of FDA workforce) are furloughed as available funding is used up; certain pending device applications may be affected.
  • Ongoing for Duration of Shutdown — Excepted employees (17% of FDA workforce) continue to work without appropriations.


, ,

Shutdown will Impact FDA Headshot

Alistair McIntyre

Alistair McIntyre focuses on patent prosecution and litigation pertaining to the biotech industry.

Alistair received his J.D. from UC Berkeley Law, where he was a member of and contributor to the Berkeley Technology Law Journal and involved with the Samuelson Law, Technology & Public Policy Clinic. Prior, Alistair received a Bachelor’s degree in Biomedical Engineering at the University of Minnesota and a Master’s degree in Bioengineering from UC San Diego.

View all posts published by Alistair McIntyre
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal